Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Otsuka buys PDL's IV Busulfex for $200mm

Executive Summary

In line with its planned asset sales and reorganization, PDL BioPharma (treatments for life-threatening diseases) has sold Otsuka Pharmaceutical Co. all rights to its IV Busulfex (busulfan) oncology product for $200mm cash.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Includes Contract

Related Companies